

In the claims:

Claims 1-31 canceled

32. (Original) A method of modulating the immune system in an animal to an antigen by implanting within the body of said animal an immune modulation device comprising an impermeable biocompatible shell having an outer surface with plurality of pores of suitable size to allow the ingress and egress of immune cells and said impermeable biocompatible shell having an interior lumen, a biocompatible fibrous scaffolding being disposed within said interior lumen, said interior lumen containing a quantity of antigen sufficient to provoke an immune response.

33. (Original) The method of claim 32 wherein the antigen is bioavailable at the time the immune modulation device is implanted into said animal.

34. (Original) The method of claim 32 wherein the antigen becomes bioavailable after the immune modulation device is implanted into said animal.

35. (Original) The method of claim 32 wherein the quantity of antigen and the timing of the bioavailability of said antigen within the immune modulation device relative to the time of implantation of the immune modulation device into said animal results in inducing or enhancing the immune response to said antigen.

36. (Original) The method of claim 32 wherein the quantity of antigen and the timing of the bioavailability of said antigen within said immune modulation device relative to the time of implantation of said immune modulation device into said animal is sufficient to result in suppressing or down regulating an existing or potential immune response to said antigen.

37. (Original) The method of claim 32 wherein multiple antigens are present in the device in amounts sufficient to provoke an immune response.

38. (Original) The method of claim 32 wherein only a portion of the antigen is bioavailable at a time the immune modulation device is implanted.

39. (Original) The method of claim 37 wherein only a portion of the multiple antigens are bioavailable at a time the immune modulation device is implanted.

40. (Original) The method of claim 32 wherein only a portion of the antigen is bioavailable at 3 days after implantation of the immune modulation device.

Claims 41-52 canceled